Comparative Study of TACE Treatment and TACE Combined with Iodine 125 Radiation Particle Implantation in the Treatment of Advanced Hepatocellular Carcinoma
Abstract 【Objective】To investigate the clinical effects of TACE combined with iodine 125 radiation particle implantation in the treatment of patients with advanced hepatocellular carcinoma. 【Methods】A retrospective analysis of 100 patients with advanced hepatocellular carcinoma from our hospital was studied. According to the treatment, there were 55 patients in the combined group (TACE combined with iodine 125 radiation particle implantation) and 45 cases in TACE group (only treated with TACE). Chemotherapy effects, serum ALT, AST,AFP,TBIL,NGAL, MMP9 and toxic side effects were compared between the two groups. 【Results】The CR and PR rate of the combined group was 65.45%, which was higher than that of the TACE group 46.67% (P<0.05). Before treatment, the serum levels of ALT, AST, AFP, TBIL, NGAL and MMP9 in two groups were not statistically significant (P>0.05). After treatment, the AFP, NGAL, and MMP9 levels in the combined group were lower than those in the TACE group (P<0.05). The incidence of nausea and abdominal pain in the combined group was significantly higher than that in the TACE group (P<0.05). The incidence of vomiting, diarrhea, and liver damage in the combined group was not significantly different from that in the TACE group (P>0.05). The median survival time was 14.0 months in the combined group and 9.0 months in the control group. The difference between the two groups was statistically significant (P<0.05).【Conclusion】TACE combined with iodine 125 radioactive particle implantation in patients with middle and late stage liver cancer is better than simple TACE surgery, but it may aggravate the incidence of side effects in patients.
DU Qian-ying,YAN Xun-cheng,DAI Zhi-jing, et al. Comparative Study of TACE Treatment and TACE Combined with Iodine 125 Radiation Particle Implantation in the Treatment of Advanced Hepatocellular Carcinoma[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(1): 47-50.
[1] 李文会, 戴真煜, 万豪光,等. 125I粒子条联合门静脉支架及TACE序贯索拉非尼治疗肝癌合并门静脉主干癌栓[J].中华医学杂志, 2016, 96(23):1838-1842. [2] Li M, He J, Pan M, et al. Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3-5 cm: A propensity score matching study[J].Dig Liver Dis,2016, 48(9):1082. [3] 蒋丽, 韩东明, 胡鸿涛,等. 125I粒子植入联合肝动脉化疗栓塞术预防原发性肝癌合并门静脉癌栓消化道出血[J].中华放射学杂志, 2016, 50(10):784-788. [4] Hu HT, Luo JP, Li HL, et al. Transarterial chemoembolization combined with computed tomography-guided 125iodine implantation enhances survival in hepatocellular carcinoma patients with portal vein tumor thrombus[J].Oncotarget,2017, 8(17):29258-29268. [5] 白晨光, 郭震, 陆游,等. 能谱CT单能量成像在去除肝癌经导管动脉化疗栓塞术治疗后碘油硬化伪影的应用[J].中国医学影像学杂志, 2016, 24(8):585-587. [6] 何川东, 周莹, 黄丹,等. 宝石CT能谱成像在肝癌经皮肝动脉化疗栓塞术后疗效评估及随访中的应用价值[J].介入放射学杂志, 2016, 25(1):34-39. [7] 曹贵文, 杜苗苗, 崔新江,等. TACE联合~125I放射性粒子植入序贯治疗近心旁原发性肝细胞肝癌效果观察[J].山东医药, 2017, 57(10):55-57. [8] Wang J, Shen JL.Spectral CT in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma: A retrospective study[J].Medicine,2017, 96(52):e9236. [9] 徐康洁, 郭小超, 刘建新,等. 双能量CT 虚拟单能量重建技术显示肝癌TACE 术后碘油沉积的价值[J].放射学实践, 2016, 31(4):321-325.
2021, Vol. 38 
